Hemoperfusion in Maintenance Hemodialysis Patients

Wei Lu; Gengru Jiang; Shanghai HP-HD Consensus Group

doi:10.1159/000525952

Hemoperfusion in Maintenance Hemodialysis Patients

Blood Purif. 2022 Aug 11:1-9. doi: 10.1159/000525952. Online ahead of print.

Authors

Wei Lu¹, Gengru Jiang^{1

2

3}; Shanghai HP-HD Consensus Group

Affiliations

¹ Renal Division, Department of Internal Medicine, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Centre for Rare Disease, Shanghai, China.
³ Shanghai Medical Association Society of Nephrology, Shanghai, China.

PMID: 35952627
DOI: 10.1159/000525952

Abstract

The accumulation of protein-bound uremic toxins and medium-large molecule toxins in maintenance hemodialysis (MHD) patients is one of the causes of long-term dialysis-related complications. Hemoperfusion can remove these uremic toxins and reduce the complications of MHD patients. Upon a review of the Chinese and international literature, combined with practical experience of clinical diagnosis and treatment, the Shanghai Medical Association Society of Nephrology reached a consensus on the clinical applications of hemoperfusion in MHD patients. This consensus included four aspects: selection of appropriate patients, treatment frequency, treatment methods, and adverse reactions and precautions and provided guidelines for the rational and standardized treatment of hemoperfusion in MHD patients.

Keywords: Appropriate patients; Hemoperfusion; Maintenance hemodialysis; Shanghai consensus; Treatment frequency.

Publication types

Review